Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following He... ( SAN DIEGO April 15 /- Cardium The...)

HOME >> MEDICINE >> TECHNOLOGY

Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack

Date:4/15/2008

SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- Cardium Therapeutics (Amex: CXM) and its operating unit InnerCool Therapies announced today that positive findings from a preclinical study, demonstrating a new and expanded benefit of early rapid hyperthermia (cooling) for the potential treatment of acute myocardial infarction (heart attack), has been published online by BioMed Central (BMC) Cardiovascular Disorders (2008, 8:7, April 10, 2008).

(Photo: http://www.newscom.com/cgi-bin/prnh/20080415/LATU038)

(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)

The study, conducted by a team of interventional cardiologists at the Lund University Hospital, Sweden, evaluated the effect of early and rapid cooling induced by a combination of cold saline infusion along with InnerCool's endovascular Celsius Control(TM) System, before or immediately after reperfusion when coronary blood flow was restored in the heart in a porcine heart attack model. Results from this study demonstrated that rapid cooling (to <35 degrees Celsius) prior to reperfusion significantly reduced overall myocardial infarct size (a measure of tissue damage in the heart) and protected the heart from other injury.

"We believe that InnerCool's low-profile, high-performance endovascular cooling system has the capacity to achieve rapid cooling within the short time available before coronary reperfusion must occur in order to potentially limit the amount of damage due to reperfusion injury following heart attack," stated Christopher J. Reinhard, Chairman and Chief Executive Officer of
'/>"/>

SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related medicine technology :

1. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007
2. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722
3. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
4. Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
5. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
6. Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs
7. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
8. Vital Therapies Announces Presentation of ELAD(R) Artificial Liver Data at American Association for the Study of Liver Diseases 2007 Annual Meeting
9. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
10. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
11. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias

Post Your Comments:

(Date:8/17/2008)...- Pharmaxis,(ASX: PXS; Nasd...hase 3,clinical trial of Bronchitol for the treatm...The first efficacy data from the trial is expected...e trial commenced its dosing phase in,April 2007, ...ects in June,2008 and closed today with 325 subjec...

(Date:8/14/2008)... showing clinical benefit in cancer,patients; Blin... and attack cancer ce.../ -- Micromet, Inc.,(Nasdaq: MITI ), a biopharmac...bodies for the treatment of cancer, inflammation a...n of a Phase 1 clinical study(1) on its,BiTE(R) an...

(Date:8/13/2008)...all/ -- As biotechnology,pharmaceutical and medic...als beyond their own borders to other parts of the...rica, complicated regulatory environments,challeng...o an analysis by,Aon Corporation (NYSE: AOC ). Ao...ompanies a visual representation of the complex in...

(Date:8/13/2008).../ -- Today positron emission,tomography (PET) scan...gy,tool for diagnosis, staging and monitoring. It ...logy emitting a radioactive tracer to localize,tum...normal tissue. As a,result, the malignant tissue s... spot.", The use of multiple imaging technologies...

Breaking Medicine Technology:Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment 2 Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 2 Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 3 Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 4 Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 5 Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 6 Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 2 Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 3 Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 4 Are PET Scans Beneficial During Cancer Diagnosis, Staging and Monitoring? 2 Seeking sustainability in a world of instability 2198 1 Seeking sustainability in a world of instability 2198 2 Duragesic Trials Continue Plaintiffs Optimistic After Latest Recall 11870 1 Duragesic Trials Continue Plaintiffs Optimistic After Latest Recall 11870 2 Cancer Drug Works Against MS in Early Trial 11869 1 Cancer Drug Works Against MS in Early Trial 11869 2 Cancer Drug Works Against MS in Early Trial 11869 3 Warner Chilcott Announces Earnings Release Date and Conference Call for Fourth Quarter and Full Year 2007 Financial Results 3275 1

[1] Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment [0] Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab [0] Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders [0] Are PET Scans Beneficial During Cancer Diagnosis, Staging and Monitoring?

...wire-FirstCall/ -- Vical,Incorporated today announ...ith the company,s Vaxfectin(TM) adjuvant generated...nformulated vaccine,at the same dose in a recently...steur,s Fluzone(R) commercial vaccine with,Vaxfect...vaccine,dose while generating equivalent or better...

...Apr 10, 2007 - Valeant,Pharmaceuticals Internation...hase 2 data for retigabine, a first-in-class,neuro...ing,independent, scientific journal. The authors c...monstrated reduction in monthly,seizure rates in t...d RESTORE2) are currently underway to further inve...

Other Medicine Technology:Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine 2 Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine 3 Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine 4 Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine 5 Valeant Pharmaceuticals Announces Publication of Retigabine Phase 2,Study Data in Neurology 2 Valeant Pharmaceuticals Announces Publication of Retigabine Phase 2,Study Data in Neurology 3

Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine Valeant Pharmaceuticals Announces Publication of Retigabine Phase 2,Study Data in Neurology

(Date:8/20/2008)...r-old Contestant Wins Trip to Little League Baseba... The National Spit Tobacco Education,Program (NSTE...st today,and encouraged young baseball players to...ddiction and the health risks of using tobacco pro...year,s slogan contest winner is,Joe Reck, a nine-y...

(Date:8/20/2008)...cently enacted Medicare Improvement Law immediatel...re Advantage insurance companies .../PRNewswire/ -- When the House and Senate,overrode...gislation,protecting Medicare beneficiaries, they ...e Advantage plans during one of the busiest months...

(Date:8/20/2008)...T CREEK, Calif., Aug. 20 /PRNewswire-FirstCall/ --... reported preliminary income from,continuing opera...f $27.5,million, or $0.76 per diluted share, inclu...er diluted share, related to provisions for store,... a 6.8 percent increase,compared with income from ...

(Date:8/20/2008)...FIELD, Mich., Aug. 20 /PRNewswire/ -- WXYZ- TV/Cha...llness Promotion will give thousands of,Detroit me...ALTHY LIVING,FOR KIDS" program. This year the prog....m. to 5 p.m. at the Charles H. Wright Museum of A...77, "Healthy Living for Kids",has provided free im...

[0] Slogan Contest Educates Young Baseball Players About the Dangers of Tobacco Use [0] Medicare Advantage Plans Struggle to Comply With New Federal Law [0] Longs Drug Stores Corporation Reports Second Quarter Results [0] WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History

...ST, the peer-reviewed journal of the American Coll...dietary intake of certain nutrients increases the ... especially in teens who smoke. Teenagers who for...e a harder time catching their breath. Furthermore...

...2007, issue of Neurology, the medical journal of t...ly Parkinsons disease report a higher than anticip...leepiness, and swelling. By identifying risk fact...isions, allow for early intervention and possibly ...

...mpaign to boost fruit and vegetable intake among y... Professor Janet Cade and colleagues of Leeds Un...nd Vegetable Scheme (SFVS), installed in 2004, on ... the north of England. A specially devised measure...

...therapy (HRT) should not be prescribed to older wo...ent chronic conditions such as heart disease . But...hort term treatment for younger women in early men...oms and improve quality of life. In 2002, the Wom...

Other Medicine News:Health News:Apple a Day Keeps Asthma Away 2 Health News:Apple a Day Keeps Asthma Away 3 Health News:Early Parkinsons Show Hallucination,sleepiness 2 Health News:Britains Free Fruit -And -Vegetable -Scheme Falls Flat 2 Health News:Study Confirms No HRT Benefit for Older Women 2 Health News:Study Confirms No HRT Benefit for Older Women 3

Apple a Day Keeps Asthma Away Early Parkinsons Show Hallucination,sleepiness Britains Free Fruit -And -Vegetable -Scheme Falls Flat Study Confirms No HRT Benefit for Older Women

...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...

Medicine Products:

Allergen, Food, Cherry Allergen, Food, Chicken Allergen, Food, Casein Allergen, Food, Blueberry

Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following He...( SAN DIEGO April 15 /- Cardium The...),Health